Luveltamab tazevibulin, an antifolate receptor alpha (FRα) antibody-drug conjugate (ADC), in combination with bevacizumab (bev) in patients with recurrent high-grade epithelial ovarian cancer (EOC): STRO-002-GM2 phase I study (ESMO 2024) - Jul 25, 2024 - Abstract #749P; Pres time: Sep 14, 2024; 09:00 AM - 05:00 PM; Location: Hall 6 - Poster area; P1 | "Encouraging antitumor activity was observed irrespective of FRa expression and prior bev treatment. This combination may offer a non-biomarker driven approach. Luvelta + bev had no new safety signals vs either alone."
Clinical • Combination therapy • P1 data • Oncology • Ovarian Cancer • Solid Tumor • FOLR1
|
|
L.P. Martin1; D. Uyar2; A. Madariaga3; A.I. Spira4; A. Oaknin5; R. Schilder6; E.M. Guerra Alia7; E.P. Hamilton8; R..W. Naumann9; D. Lorusso10; L. Lu11; C.J. Berman12; A.E. Borgman12; J.W. Moroney13
|